Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62021TA0644

    Case T-644/21: Judgment of the General Court of 21 December 2022 — Pharmadom v EUIPO — Wellbe Pharmaceuticals (WellBe PHARMACEUTICALS) (EU trade mark — Opposition proceedings — Application for the EU figurative mark WellBe PHARMACEUTICALS — Earlier national word mark WELL AND WELL — Relative ground for refusal — No likelihood of confusion — No similarity between the signs — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))

    OJ C 83, 6.3.2023, p. 21–21 (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    6.3.2023   

    EN

    Official Journal of the European Union

    C 83/21


    Judgment of the General Court of 21 December 2022 — Pharmadom v EUIPO — Wellbe Pharmaceuticals (WellBe PHARMACEUTICALS)

    (Case T-644/21) (1)

    (EU trade mark - Opposition proceedings - Application for the EU figurative mark WellBe PHARMACEUTICALS - Earlier national word mark WELL AND WELL - Relative ground for refusal - No likelihood of confusion - No similarity between the signs - Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))

    (2023/C 83/25)

    Language of the case: English

    Parties

    Applicant: Pharmadom (Boulogne-Billancourt, France) (represented by: M.-P. Dauquaire, lawyer)

    Defendant: European Union Intellectual Property Office (represented by: D. Walicka, acting as Agent)

    Other party to the proceedings before the Board of Appeal of EUIPO: Wellbe Pharmaceuticals S.A. (Warsaw, Poland)

    Re:

    By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the Fifth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 12 July 2021 (Case R 1423/2020-5).

    Operative part of the judgment

    The Court:

    1.

    Dismisses the action;

    2.

    Orders Pharmadom to pay the costs.


    (1)  OJ C 37, 24.1.2022.


    Top